Semaglutide vs tirzepatide vs retatrutide: what the evidence shows

Mechanism: one, two, or three receptors

The core distinction between these three molecules is not potency but pharmacology. Semaglutide is a selective agonist at the GLP-1 receptor. Tirzepatide is a single peptide engineered to activate both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Retatrutide extends this further, acting as an agonist at GLP-1, GIP, and glucagon receptors simultaneously.

Each added receptor target is thought to contribute a distinct physiological effect. GLP-1 receptor activation slows gastric emptying, promotes satiety signalling in the hypothalamus and brainstem, and enhances glucose-dependent insulin secretion. GIP receptor activation appears to improve insulin sensitivity and may modulate adipose tissue metabolism, though its net contribution to weight loss when combined with GLP-1 agonism is still debated mechanistically even though the clinical effect is well documented. Glucagon receptor agonism increases energy expenditure and hepatic fat oxidation, a property unique to retatrutide among the three.

The trial programmes at a glance

Each molecule has (or is building) its own dedicated clinical trial programme, generally structured to first establish glycemic efficacy in type 2 diabetes and then chronic weight management in people with or without diabetes.

• Semaglutide: STEP trials (chronic weight management, various populations including adolescents and people with knee osteoarthritis), SUSTAIN trials (type 2 diabetes), SELECT (cardiovascular outcomes).
• Tirzepatide: SURPASS trials (type 2 diabetes), SURMOUNT trials (chronic weight management, including SURMOUNT-5, the head-to-head trial against semaglutide), SUMMIT (heart failure with preserved ejection fraction).
• Retatrutide: a Phase 2 obesity trial (Jastreboff et al., NEJM 2023) and a Phase 2 type 2 diabetes trial, with the Phase 3 TRIUMPH programme underway to evaluate weight management, cardiometabolic risk reduction, and other indications.

Weight-loss outcomes reported in each programme

In STEP 1, adults without diabetes who received semaglutide 2.4 mg weekly for 68 weeks lost a mean of roughly 15% of baseline body weight versus about 2.4% with placebo, on a treatment-policy estimand basis. In SURMOUNT-1, tirzepatide at the highest evaluated dose (15 mg) produced mean weight loss of roughly 21% over 72 weeks, versus about 3% with placebo, in adults with obesity or overweight without diabetes. In the Phase 2 retatrutide obesity trial, the highest dose (12 mg) was associated with mean weight loss of roughly 24% at 48 weeks, the largest mean effect reported for an incretin-based therapy in a randomized trial to date.

These are protocol-condition group means from separate trials with different populations, durations, and dose-escalation schemes — they are not a validated ranking of what any individual would experience, and they must not be read as a three-way head-to-head. The one genuine head-to-head data point is SURMOUNT-5, which compared tirzepatide directly against semagludide within a single randomized trial.

Glycemic (HbA1c) outcomes in type 2 diabetes

In SUSTAIN trials, semaglutide 1.0–2.0 mg weekly reduced HbA1c by roughly 1.5–1.8 percentage points depending on trial and comparator. In SURPASS trials, tirzepatide reduced HbA1c by roughly 2.0–2.4 percentage points across doses, generally outperforming both placebo and active comparators including semaglutide 1 mg in SURPASS-2, a direct head-to-head within the diabetes programme. Retatrutide's Phase 2 diabetes trial reported HbA1c reductions in a broadly similar range to tirzepatide at higher doses, though this remains a smaller, earlier-stage dataset pending Phase 3 confirmation.

SURPASS-2 is worth flagging separately from SURMOUNT-5: it was conducted in people with type 2 diabetes and used semaglutide 1 mg (not the 2.4 mg weight-management dose), so it answers a different clinical question than SURMOUNT-5's obesity-population comparison at semaglutide 2.4 mg.

Cardiovascular and hepatic data

Semaglutide has the most mature cardiovascular outcomes evidence of the three. SELECT, a dedicated cardiovascular outcomes trial in adults with established cardiovascular disease and overweight or obesity but without diabetes, found that semaglutide 2.4 mg reduced the incidence of a composite endpoint of major adverse cardiovascular events versus placebo. This trial was a major factor in expanding semaglutide's approved indications to include cardiovascular risk reduction in appropriate patients.

Tirzepatide does not yet have a completed general-population cardiovascular outcomes trial of the same design as SELECT, though the SUMMIT trial demonstrated benefit in a specific population with heart failure with preserved ejection fraction and obesity. Dedicated tirzepatide cardiovascular outcomes trials in broader populations are ongoing. Retatrutide's cardiovascular outcomes data is the least mature of the three; cardiometabolic endpoints are being evaluated within the TRIUMPH Phase 3 programme but long-term hard-outcome data is not yet available.

All three mechanisms have shown reductions in liver fat content in substudies or dedicated trials, and interest in these molecules for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) is active across the class. Semaglutide has been studied in dedicated MASH trials; tirzepatide and retatrutide have shown favorable liver-fat signals in substudies of their broader weight and diabetes trials. Cross-mechanism magnitude comparisons here are especially premature given differing trial designs, imaging methods, and populations.

Tolerability and discontinuation

Across all three molecules, the dominant adverse events are gastrointestinal: nausea, vomiting, diarrhea, and constipation, generally most frequent during dose escalation and decreasing with continued treatment at a stable dose. Discontinuation rates due to adverse events are generally in a broadly similar range across the three trial programmes, though retatrutide's Phase 2 data, being an earlier and smaller dataset, warrants more caution before drawing firm tolerability conclusions relative to the larger, more mature semaglutide and tirzepatide Phase 3 safety databases.

Gallbladder-related events, injection-site reactions, and, less commonly, pancreatitis have been reported across the class in postmarketing and trial data; product labeling for approved agents details specific warnings and contraindications that are beyond the scope of a comparative efficacy summary.

Regulatory and approval status

As of this writing, semaglutide is FDA-approved under multiple brand names for type 2 diabetes (Ozempic, injectable; Rybelsus, oral) and for chronic weight management (Wegovy), and carries an approved cardiovascular risk-reduction indication in eligible adults. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Retatrutide has not received regulatory approval for any indication and remains an investigational compound studied under the TRIUMPH Phase 3 programme; timelines for potential approval are not yet public and should not be assumed.

Why cross-trial comparison is not the same as head-to-head evidence

It is common to see tables online stacking STEP, SURMOUNT, and retatrutide Phase 2 topline percentages side by side as though they were arms of a single trial. They were not. Differences in trial duration, dose-escalation schedule, baseline body weight and demographics, background lifestyle intervention intensity, region, and statistical estimand (treatment-policy including people who discontinued, versus on-treatment/per-protocol) can all shift topline numbers independent of the drug's biological effect.

Where a genuine head-to-head randomized trial exists — SURMOUNT-5 for tirzepatide versus semaglutide in obesity, or SURPASS-2 for tirzepatide versus semaglutide in type 2 diabetes — that evidence should be weighted far more heavily than juxtaposed placebo-controlled trial toplines. No completed head-to-head trial yet directly compares retatrutide against either semaglutide or tirzepatide; until TRIUMPH or another dedicated comparative trial reports, any claim about retatrutide being definitively 'stronger' than the other two rests on cross-trial inference, not direct comparative evidence.